IOVA
Iovance Biotherapeutics, Inc.
Price Chart
Latest Quote
$4.21
-0.04 (-0.94%)
Current Price
| Previous Close | $4.25 |
| Open | $4.24 |
| Day High | $4.34 |
| Day Low | $4.14 |
| Volume | 6,635,224 |
Stock Information
| Shares Outstanding | 446.50M |
| Total Debt | $47.78M |
| Cash Equivalents | $313.44M |
| Revenue | $285.61M |
| Net Income | $-353.86M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.88B |
| EPS (TTM) | $-0.92 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.63B |
| Sales | $285.61M |
| Income | $-353.86M |
| Book/sh | $1.65 |
| Cash/sh | $0.70 |
| Employees | 975 |
Financial Ratios
| Quick Ratio | 3.05 |
| Current Ratio | 3.60 |
| Debt/Eq | 6.62 |
Returns & Margins
| ROA | -23.65% |
| ROE | -47.51% |
| Gross Margin | 39.44% |
| Operating Margin | -113.46% |
| Profit Margin | -123.90% |
Ownership
| Insider Ownership | 0.34% |
| Institutional Ownership | 67.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -13.18 |
| P/S | 6.57 |
| P/B | 2.55 |
Analyst Data
| Recommendation | buy |
| Target Price | $8.80 |
Technical Indicators
| SMA20 | $4.06 |
| SMA50 | $3.82 |
| SMA200 | $3.01 |
| RSI | 45.74 |
| ATR | 0.3350 |
| Shares Float | 387.90M |
| Short Float | 24.99% |
| Short Ratio | 6.78 |
| Volatility | 0.70 |
| Rel Volume | 0.50 |
Performance History
| Week | +7.00% |
| Month | +2.56% |
| Quarter | +12.13% |
| 6 Months | +51.26% |
| YTD | +66.87% |
| Year | +123.67% |
| 3 Years | -49.21% |
| 5 Years | -82.92% |
| 10 Years | -43.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $4.20 | 6,635,224 |
| 2026-06-24 | $4.25 | 15,579,800 |
| 2026-06-23 | $4.44 | 17,975,900 |
| 2026-06-22 | $4.06 | 11,624,400 |
| 2026-06-18 | $3.91 | 23,714,700 |
| 2026-06-17 | $3.93 | 11,208,000 |
| 2026-06-16 | $3.82 | 9,004,000 |
| 2026-06-15 | $4.03 | 12,659,300 |
| 2026-06-12 | $4.08 | 10,967,900 |
| 2026-06-11 | $3.96 | 11,510,900 |
| 2026-06-10 | $3.78 | 8,880,500 |
| 2026-06-09 | $3.88 | 11,270,600 |
| 2026-06-08 | $4.00 | 11,287,500 |
| 2026-06-05 | $4.23 | 19,690,900 |
| 2026-06-04 | $4.38 | 22,604,300 |
| 2026-06-03 | $3.79 | 9,667,600 |
| 2026-06-02 | $4.10 | 12,715,800 |
| 2026-06-01 | $3.96 | 14,459,000 |
| 2026-05-29 | $4.10 | 17,279,200 |
| 2026-05-28 | $4.30 | 9,266,000 |
| 2026-05-27 | $4.37 | 12,819,900 |
| 2026-05-26 | $4.10 | 14,576,900 |
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
đ° Latest News
Iovance (IOVA) Surges 9.4% on Regulatory Nod
Insider Monkey âĸ 2026-06-24T02:18:46Z
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-06-23T23:53:07Z
H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA)
Insider Monkey âĸ 2026-06-16T18:46:00Z
Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?
Insider Monkey âĸ 2026-06-13T15:30:57Z
Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001
Insider Monkey âĸ 2026-06-10T18:22:54Z
Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption
Insider Monkey âĸ 2026-06-07T17:57:34Z
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For Amtagvi
Simply Wall St. âĸ 2026-06-07T01:09:01Z
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?
Insider Monkey âĸ 2026-06-06T00:11:45Z
Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15%
Insider Monkey âĸ 2026-06-05T01:28:09Z
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
Motley Fool âĸ 2026-06-02T04:35:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $161,799,000 | $82,780,000 | $1,033,000 | $0 |
| Cost Of Revenue | $173,184,000 | $93,248,000 | $1,033,000 | $0 |
| Total Revenue | $263,502,000 | $164,070,000 | $1,189,000 | $0 |
| Operating Revenue | $268,005,000 | $169,170,000 | $1,192,000 | $0 |
| Expenses | ||||
| Total Expenses | $661,715,000 | $559,348,000 | $461,748,000 | $398,878,000 |
| Other Income Expense | $-5,143,000 | - | - | - |
| Net Non Operating Interest Income Expense | $10,307,000 | $20,273,000 | $13,043,000 | $2,985,000 |
| Operating Expense | $488,531,000 | $466,100,000 | $460,715,000 | $398,878,000 |
| General And Administrative Expense | - | - | - | $104,097,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-390,978,000 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Net Interest Income | $10,307,000 | $20,273,000 | $13,043,000 | $2,985,000 |
| Interest Income | $10,307,000 | $20,273,000 | $13,043,000 | $2,985,000 |
| Normalized Income | $-385,862,258 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Net Income From Continuing And Discontinued Operation | $-390,978,000 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Total Operating Income As Reported | $-403,356,000 | $-395,278,000 | $-460,559,000 | $-398,878,000 |
| Net Income Common Stockholders | $-390,978,000 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Net Income | $-390,978,000 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Net Income Including Noncontrolling Interests | $-390,978,000 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Net Income Continuous Operations | $-390,978,000 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Pretax Income | $-393,049,000 | $-375,005,000 | $-447,516,000 | $-395,893,000 |
| Special Income Charges | $-5,143,000 | $0 | $0 | - |
| Interest Income Non Operating | $10,307,000 | $20,273,000 | $13,043,000 | $2,985,000 |
| Operating Income | $-398,213,000 | $-395,278,000 | $-460,559,000 | $-398,878,000 |
| Depreciation Amortization Depletion Income Statement | $35,939,000 | $37,603,000 | $21,423,000 | - |
| Depreciation And Amortization In Income Statement | $35,939,000 | $37,603,000 | $21,423,000 | - |
| Gross Profit | $90,318,000 | $70,822,000 | $156,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-1.09 | $-1.28 | $-1.89 | $-2.49 |
| Basic EPS | $-1.09 | $-1.28 | $-1.89 | $-2.49 |
| Other | ||||
| Tax Effect Of Unusual Items | $-27,258 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-345,746,000 | $-347,207,000 | $-427,432,000 | $-377,743,000 |
| Total Unusual Items | $-5,143,000 | $0 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-5,143,000 | $0 | $0 | - |
| Reconciled Depreciation | $47,324,000 | $48,071,000 | $33,127,000 | $21,135,000 |
| EBITDA (Bullshit earnings) | $-350,889,000 | $-347,207,000 | $-427,432,000 | $-377,743,000 |
| EBIT | $-398,213,000 | $-395,278,000 | $-460,559,000 | $-398,878,000 |
| Diluted Average Shares | $357,345,000 | $289,877,000 | $235,131,000 | $159,259,000 |
| Basic Average Shares | $357,345,000 | $289,877,000 | $235,131,000 | $159,259,000 |
| Diluted NI Availto Com Stockholders | $-390,978,000 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Tax Provision | $-2,071,000 | $-2,828,000 | $-3,479,000 | $0 |
| Restructuring And Mergern Acquisition | $5,143,000 | $0 | $0 | - |
| Research And Development | $300,270,000 | $276,228,000 | $333,194,000 | $294,781,000 |
| Selling General And Administration | $152,322,000 | $152,269,000 | $106,098,000 | $104,097,000 |
| Other Gand A | - | - | - | $104,097,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $419,259,000 | $428,007,000 | $355,355,000 | $499,638,000 |
| Total Assets | $913,170,000 | $910,426,000 | $780,351,000 | $663,982,000 |
| Total Non Current Assets | $470,481,000 | $453,408,000 | $472,503,000 | $184,866,000 |
| Other Non Current Assets | $14,146,000 | $6,728,000 | $66,700,000 | $6,619,000 |
| Goodwill And Other Intangible Assets | $279,324,000 | $282,398,000 | $229,258,000 | $0 |
| Current Assets | $442,689,000 | $457,018,000 | $307,848,000 | $479,116,000 |
| Other Current Assets | $11,583,000 | $12,377,000 | $17,458,000 | $7,271,000 |
| Inventory | $51,678,000 | $51,520,000 | $10,372,000 | $0 |
| Receivables | $82,448,000 | $69,340,000 | $151,000 | $0 |
| Accounts Receivable | $82,448,000 | $69,340,000 | $151,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $296,980,000 | $323,781,000 | $279,867,000 | $471,845,000 |
| Cash And Cash Equivalents | $163,078,000 | $115,694,000 | $114,888,000 | $231,731,000 |
| Investmentin Financial Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $49,444,000 | $58,261,000 | $75,862,000 | $85,446,000 |
| Long Term Debt And Capital Lease Obligation | $44,401,000 | $45,365,000 | $68,085,000 | $72,859,000 |
| Current Debt And Capital Lease Obligation | $5,043,000 | $12,896,000 | $7,777,000 | $12,587,000 |
| Current Debt | $1,000,000 | - | - | - |
| Long Term Debt | - | $1,000,000 | $1,000,000 | $1,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $214,587,000 | $200,021,000 | $195,738,000 | $164,344,000 |
| Total Non Current Liabilities Net Minority Interest | $76,229,000 | $77,680,000 | $85,432,000 | $72,859,000 |
| Non Current Deferred Liabilities | $31,828,000 | $32,315,000 | $17,347,000 | $0 |
| Non Current Deferred Taxes Liabilities | $31,828,000 | $32,315,000 | $17,347,000 | $0 |
| Current Liabilities | $138,358,000 | $122,341,000 | $110,306,000 | $91,485,000 |
| Current Notes Payable | $1,000,000 | $0 | - | - |
| Payables And Accrued Expenses | $133,315,000 | $109,445,000 | $102,529,000 | $78,898,000 |
| Payables | $22,159,000 | $27,509,000 | $33,123,000 | $26,603,000 |
| Accounts Payable | $22,159,000 | $27,509,000 | $33,123,000 | $26,603,000 |
| Equity | ||||
| Common Stock Equity | $698,581,000 | $710,402,000 | $584,610,000 | $499,635,000 |
| Preferred Stock Equity | $2,000 | $3,000 | $3,000 | $3,000 |
| Total Equity Gross Minority Interest | $698,583,000 | $710,405,000 | $584,613,000 | $499,638,000 |
| Stockholders Equity | $698,583,000 | $710,405,000 | $584,613,000 | $499,638,000 |
| Gains Losses Not Affecting Retained Earnings | $16,440,000 | $-1,046,000 | $2,526,000 | $-902,000 |
| Other Equity Adjustments | $16,440,000 | $-1,046,000 | $2,526,000 | $-902,000 |
| Retained Earnings | $-2,775,530,000 | $-2,384,552,000 | $-2,012,375,000 | $-1,568,338,000 |
| Other | ||||
| Ordinary Shares Number | $411,938,061 | $305,252,194 | $256,135,715 | $187,812,072 |
| Share Issued | $411,938,061 | $305,252,194 | $256,135,715 | $187,812,072 |
| Tangible Book Value | $419,257,000 | $428,004,000 | $355,352,000 | $499,635,000 |
| Invested Capital | $699,581,000 | $711,402,000 | $585,610,000 | $500,635,000 |
| Working Capital | $304,331,000 | $334,677,000 | $197,542,000 | $387,631,000 |
| Capital Lease Obligations | $48,444,000 | $57,261,000 | $74,862,000 | $84,446,000 |
| Total Capitalization | $698,583,000 | $711,405,000 | $585,613,000 | $500,638,000 |
| Additional Paid In Capital | $3,457,654,000 | $3,095,987,000 | $2,594,448,000 | $2,068,867,000 |
| Capital Stock | $19,000 | $16,000 | $14,000 | $11,000 |
| Common Stock | $17,000 | $13,000 | $11,000 | $8,000 |
| Preferred Stock | $2,000 | $3,000 | $3,000 | $3,000 |
| Long Term Capital Lease Obligation | $44,401,000 | $44,365,000 | $67,085,000 | $71,859,000 |
| Current Capital Lease Obligation | $4,043,000 | $12,896,000 | $7,777,000 | $12,587,000 |
| Current Accrued Expenses | $111,156,000 | $81,936,000 | $69,406,000 | $52,295,000 |
| Net PPE | $177,011,000 | $164,282,000 | $176,545,000 | $178,247,000 |
| Accumulated Depreciation | $-48,770,000 | $-36,020,000 | $-27,913,000 | $-16,718,000 |
| Gross PPE | $225,781,000 | $200,302,000 | $204,458,000 | $194,965,000 |
| Leases | $90,385,000 | $67,375,000 | $76,804,000 | $74,305,000 |
| Construction In Progress | $35,649,000 | $34,938,000 | $24,101,000 | $9,118,000 |
| Other Properties | $84,704,000 | $86,668,000 | $91,636,000 | $101,102,000 |
| Machinery Furniture Equipment | $15,043,000 | $11,321,000 | $11,917,000 | $10,440,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $-7,875,000 | - | - | - |
| Finished Goods | $22,827,000 | $15,012,000 | $4,623,000 | $0 |
| Work In Process | $5,044,000 | $8,765,000 | $5,749,000 | $0 |
| Raw Materials | $31,682,000 | $27,743,000 | $0 | - |
| Other Short Term Investments | $133,902,000 | $208,087,000 | $164,979,000 | $240,114,000 |
| Investments And Advances | - | - | - | $0 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-336,244,000 | $-364,046,000 | $-384,110,000 | $-313,182,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-302,408,000 | $-352,977,000 | $-361,820,000 | $-292,757,000 |
| Cash Flow From Continuing Operating Activities | $-302,408,000 | $-352,977,000 | $-361,820,000 | $-292,757,000 |
| Operating Gains Losses | $-194,000 | $1,612,000 | $70,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-33,836,000 | $-11,069,000 | $-22,290,000 | $-20,425,000 |
| Investing Cash Flow | $47,496,000 | $-96,411,000 | $-155,242,000 | $256,455,000 |
| Cash Flow From Continuing Investing Activities | $47,496,000 | $-96,411,000 | $-155,242,000 | $256,455,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $306,307,000 | $397,304,000 | $463,281,000 | $189,502,000 |
| Financing Cash Flow | $300,773,000 | $390,664,000 | $462,959,000 | $190,150,000 |
| Cash Flow From Continuing Financing Activities | $300,773,000 | $390,664,000 | $462,959,000 | $190,150,000 |
| Net Other Financing Charges | $-7,059,000 | $-12,858,000 | $-2,795,000 | $-2,649,000 |
| Net Common Stock Issuance | $306,307,000 | $397,304,000 | $463,281,000 | $189,502,000 |
| Common Stock Issuance | $306,307,000 | $397,304,000 | $463,281,000 | $189,502,000 |
| Other | ||||
| End Cash Position | $169,058,000 | $122,053,000 | $181,318,000 | $238,161,000 |
| Beginning Cash Position | $122,053,000 | $181,318,000 | $238,161,000 | $84,313,000 |
| Effect Of Exchange Rate Changes | $1,144,000 | $-541,000 | $-2,740,000 | - |
| Changes In Cash | $45,861,000 | $-58,724,000 | $-54,103,000 | $153,848,000 |
| Proceeds From Stock Option Exercised | $1,525,000 | $6,218,000 | $2,473,000 | $3,297,000 |
| Net Investment Purchase And Sale | $81,332,000 | $-32,769,000 | $79,681,000 | $276,880,000 |
| Sale Of Investment | $400,000,000 | $428,000,000 | $285,583,000 | $522,696,000 |
| Purchase Of Investment | $-318,668,000 | $-460,769,000 | $-205,902,000 | $-245,816,000 |
| Net Business Purchase And Sale | $0 | $-52,573,000 | $-212,633,000 | $0 |
| Purchase Of Business | $0 | $-52,573,000 | $-212,633,000 | $0 |
| Net PPE Purchase And Sale | $-33,836,000 | $-11,069,000 | $-22,290,000 | $-20,425,000 |
| Purchase Of PPE | $-33,836,000 | $-11,069,000 | $-22,290,000 | $-20,425,000 |
| Change In Working Capital | $-24,266,000 | $-127,021,000 | $-6,521,000 | $-2,892,000 |
| Change In Other Current Liabilities | $-10,900,000 | $-12,074,000 | $-10,794,000 | $-1,942,000 |
| Change In Payables And Accrued Expense | $21,976,000 | $737,000 | $24,602,000 | $1,180,000 |
| Change In Accrued Expense | $28,637,000 | $8,578,000 | $19,774,000 | $-4,703,000 |
| Change In Payable | $-6,661,000 | $-7,841,000 | $4,828,000 | $5,883,000 |
| Change In Account Payable | $-6,661,000 | $-7,841,000 | $4,828,000 | $5,883,000 |
| Change In Prepaid Assets | $-8,023,000 | $-2,113,000 | $-10,062,000 | $-2,130,000 |
| Change In Inventory | $-14,211,000 | $-44,382,000 | $-10,118,000 | $0 |
| Change In Receivables | $-13,108,000 | $-69,189,000 | $-149,000 | $0 |
| Changes In Account Receivables | $-13,108,000 | $-69,189,000 | $-149,000 | $0 |
| Stock Based Compensation | $61,575,000 | $109,627,000 | $62,625,000 | $84,022,000 |
| Provisionand Write Offof Assets | $13,404,000 | - | - | - |
| Amortization Of Securities | $-7,202,000 | $-10,261,000 | $-3,605,000 | $474,000 |
| Deferred Tax | $-2,071,000 | $-2,828,000 | $-3,479,000 | $0 |
| Deferred Income Tax | $-2,071,000 | $-2,828,000 | $-3,479,000 | $0 |
| Depreciation Amortization Depletion | $47,324,000 | $48,071,000 | $33,127,000 | $21,135,000 |
| Depreciation And Amortization | $47,324,000 | $48,071,000 | $33,127,000 | $21,135,000 |
| Amortization Cash Flow | $23,077,000 | $26,379,000 | $9,849,000 | $0 |
| Amortization Of Intangibles | $23,077,000 | $26,379,000 | $9,849,000 | $0 |
| Depreciation | $24,247,000 | $21,692,000 | $23,278,000 | $21,135,000 |
| Net Foreign Currency Exchange Gain Loss | $-238,000 | $-175,000 | $70,000 | $0 |
| Gain Loss On Sale Of PPE | $0 | $-5,568,000 | $0 | $0 |
| Net Income From Continuing Operations | $-390,978,000 | $-372,177,000 | $-444,037,000 | $-395,893,000 |
| Asset Impairment Charge | - | $7,355,000 | $0 | $397,000 |
| Issuance Of Debt | - | - | $0 | $0 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
Fetched: 2026-06-20